Brought to you by 
Seattle Genetics public offering nets $659mm to fund Cascadian purchase
02 Feb 2018
Executive Summary
Seattle Genetics Inc. (targeted antibody-based cancer therapies) netted $659mm through a public offering of 13.27mm common shares (including the overallotment) at $52. Proceeds will fund the firm's acquisition of Cascadian Therapeutics; on the same day it announced the FOPO, Seattle Genetics offered $10 per share or approximately $614mm to purchase the oncology drug development company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Seattle Genetics public offering nets $659mm to fund Cascadian purchase
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice